Right Now
Aikido Pharma focuses on the treatment of prostate cancer and has secured an early investment in Convergent Therapeutics, Inc. Convergent Therapeutics, Inc. is a startup pharmaceutical company focused on developing next generation radiopharmaceutical therapy for prostate cancer and other applications. Its proprietary technology involves peptide receptor radionuclide therapy (“PRRT”) developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine. For more information, visit us online or call us at 212-745-1373.
- Home - AIkido Pharma Inc.
-
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
More Posts
Map
Aikido Pharma
Get DirectionsAikido Pharma
-
One Rockefeller Plaza
New York, New York 10020
United States - (212) 745-1373
Report This Post
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.
